UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

Journal of neurochemistry, 2002-05, Vol.81 (3), p.481-496

2002

Volltextzugriff (PDF)

Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

Journal of Neural Transmission, 2007-05, Vol.114 (5), p.621-628

2007

Volltextzugriff (PDF)

Aminoterminally truncated and oxidized amyloid-beta peptide species in Alzheimer’s disease

Neuroscience, 2007-04, Vol.146 (1), p.17-18

2007

Volltextzugriff (PDF)

New perspectives in the laboratory diagnosis of dementia

Nervenarzt, 2008-11, Vol.79 Suppl 3, p.139-46; quiz 147-8

2008

Volltextzugriff (PDF)

Neue Perspektiven in der laborchemischen Diagnostik bei Demenzen

Nervenarzt, 2008-12, Vol.79 (Suppl 3), p.139-148

2008

Volltextzugriff (PDF)

Selective reduction of amyloid beta 42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation

Journal of neurology, neurosurgery and psychiatry, 2006-10, Vol.77 (10), p.1201-1203

2006

Volltextzugriff (PDF)

Selective reduction of amyloid β42 discriminates Alzheimer’s disease from Huntington’s disease: indication for distinct pathological events in amyloid β peptide aggregation

Journal of neurology, neurosurgery and psychiatry, 2006-10, Vol.77 (10), p.1201-1203

2006

Volltextzugriff (PDF)

Neurochemische Demenzdiagnostik – Quo vadis?

Nervenheilkunde, 2007, Vol.26 (10), p.861-866

2007

Volltextzugriff (PDF)

Neurochemische Frühdiagnostik und klinische Neuroproteomik demenzieller Erkrankungen

Nervenheilkunde, 2007, Vol.26 (10), p.853-860

2007

Volltextzugriff (PDF)

Urine-kinetics of Low Molecular Polyethylene Glycols Following an Oral Capsule Ingestion

Journal of Applied Life Sciences International, 2018-01, Vol.15 (4), p.1-6

2018

Volltextzugriff (PDF)

Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid β peptides

Electrophoresis, 2004-09, Vol.25 (17), p.2912-2918

2004

Volltextzugriff (PDF)

Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides

Proteomics. Clinical applications, 2012-04, Vol.6 (3-4), p.163-169

2012

Volltextzugriff (PDF)

Biomarker bei neurodegenerativen Demenzen

Aktuelle Neurologie, 2008-12, Vol.35 (10), p.526-538

2008

Volltextzugriff (PDF)

Selective reduction of amyloid 42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid peptide aggregation

Journal of neurology, neurosurgery and psychiatry, 2006-10, Vol.77 (10), p.1201-1203

Mollenhauer, B

2006

Volltextzugriff (PDF)

CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

Proteomics. Clinical applications, 2008-10, Vol.2 (10-11), p.1548-1556

2008

Volltextzugriff (PDF)

Amyloid beta peptides in plasma in early diagnosis of Alzheimer' s disease: A multicenter study with multiplexing

Experimental neurology, 2010-06, Vol.223 (2), p.366-370

2010

Volltextzugriff (PDF)

Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing : Beta-amylid and tau protein abnormalities in Alzheimer's disease

Experimental neurology, 2010, Vol.223 (2), p.366-370

2010

Volltextzugriff (PDF)

Validation of amyloid- peptides in CSF diagnosis of neurodegenerative dementias

Molecular psychiatry, 2007-07, Vol.12 (7), p.671-680

2007

Volltextzugriff (PDF)

Beta-amyloid-Peptid-Spektrum im Liquor von Patienten mit Chorea Huntington

Aktuelle Neurologie, 2005, Vol.32 (S 4)

2005

Volltextzugriff (PDF)

Tau-protein und Beta-amyloid (1–42) im Liquor bei Lewy-Body- und Parkinson-Demenz

Aktuelle Neurologie, 2005, Vol.32 (S 1)

2005

Volltextzugriff (PDF)

CSF Tau, phospho-Tau181 and amyloid-β 38/40/42 in frontotemporal dementia and pimary progressive aphasia

Aktuelle Neurologie, 2009, Vol.36 (S 02)

2009

Volltextzugriff (PDF)

The concentrations of amyloid beta 1–42, total Tau and phospho-Tau181 in the CSF of patients with early dementia and MCI as measured with multiplexing technology

Pharmacopsychiatry, 2005, Vol.38 (5)

2005

Volltextzugriff (PDF)

Tauopathies and synucleinopathies: Do cerebrospinal fluid [beta]-amyloid peptides reflect disease-specific pathogenesis?

Journal of neural transmission, 2007-07, Vol.114 (7), p.919

2007

Volltextzugriff (PDF)

Reduced CSF carboxyterminally truncated A[beta] peptides in frontotemporal lobe degenerations

Journal of neural transmission, 2007-05, Vol.114 (5), p.621

2007

Volltextzugriff (PDF)

Einfluss von multimodaler sportlicher Aktivität auf Kognition und Alltagskompetenzen bei früher Alzheimer-Demenz (SPORT&KOG)

Zeitschrift für Gerontopsychologie & -psychiatrie, 2008-09, Vol.21 (3), p.163-169

2008

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

Aminoterminally truncated and oxidized amyloid-beta peptide species in Alzheimer’s disease

New perspectives in the laboratory diagnosis of dementia

Neue Perspektiven in der laborchemischen Diagnostik bei Demenzen

Selective reduction of amyloid beta 42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation

Selective reduction of amyloid β42 discriminates Alzheimer’s disease from Huntington’s disease: indication for distinct pathological events in amyloid β peptide aggregation

Neurochemische Demenzdiagnostik – Quo vadis?

Neurochemische Frühdiagnostik und klinische Neuroproteomik demenzieller Erkrankungen

Urine-kinetics of Low Molecular Polyethylene Glycols Following an Oral Capsule Ingestion

Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid β peptides

Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides

Biomarker bei neurodegenerativen Demenzen

Selective reduction of amyloid 42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid peptide aggregation

CSF amyloid-β 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

Amyloid beta peptides in plasma in early diagnosis of Alzheimer' s disease: A multicenter study with multiplexing

Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing : Beta-amylid and tau protein abnormalities in Alzheimer's disease

Validation of amyloid- peptides in CSF diagnosis of neurodegenerative dementias

Beta-amyloid-Peptid-Spektrum im Liquor von Patienten mit Chorea Huntington

Tau-protein und Beta-amyloid (1–42) im Liquor bei Lewy-Body- und Parkinson-Demenz

CSF Tau, phospho-Tau181 and amyloid-β 38/40/42 in frontotemporal dementia and pimary progressive aphasia

The concentrations of amyloid beta 1–42, total Tau and phospho-Tau181 in the CSF of patients with early dementia and MCI as measured with multiplexing technology

Tauopathies and synucleinopathies: Do cerebrospinal fluid [beta]-amyloid peptides reflect disease-specific pathogenesis?

Reduced CSF carboxyterminally truncated A[beta] peptides in frontotemporal lobe degenerations

Einfluss von multimodaler sportlicher Aktivität auf Kognition und Alltagskompetenzen bei früher Alzheimer-Demenz (SPORT&KOG)

Aktive Filter

Suchergebnisse filtern